Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response -- Ignore unavailable to you. Want to Upgrade?

To: Gary105 who wrote (1423)	1/20/2000 2:39:00 AM
From: jake burns	Read Replies (1) \| Respond to of 1510

There are 2 Remune (Aids immunotherapeutic) trials ongoing. One is in Spain, and that should finish around December. The other is still enrolling (the pivotal usa ph. 3) and should finish enrolling in the 2nd quarter. From that point, the trial will conclude 48 weeks later, which puts it at around April 2001. The next data may be presented at the conference on retroviruses in S.F. Jan 30-feb 3. IMNR's Thai partner, Trinity, is expected to publish data from their concluded trial which examined Remune as a monotherapy (as opposed to the usa/spain trials which examine Remune as part of combination therapy). Remune should be approved for use in thailand this quarter. Good luck...al.